VistaGen Therapeutics (NASDAQ:VTGN) Cut to “Sell” at Wall Street Zen

VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

VTGN has been the subject of several other reports. Stifel Nicolaus downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Jefferies Financial Group restated a “hold” rating and set a $0.90 target price (down from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Finally, Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Four equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Price Performance

Shares of VTGN opened at $0.61 on Friday. VistaGen Therapeutics has a 1 year low of $0.43 and a 1 year high of $5.14. The stock has a 50 day simple moving average of $0.60 and a two-hundred day simple moving average of $2.38. The firm has a market cap of $24.13 million, a P/E ratio of -0.32 and a beta of 0.29.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.14 million. On average, equities analysts anticipate that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On VistaGen Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC purchased a new stake in shares of VistaGen Therapeutics during the third quarter worth about $73,000. Marshall Wace LLP purchased a new position in VistaGen Therapeutics during the 2nd quarter valued at about $69,000. OMERS ADMINISTRATION Corp bought a new position in VistaGen Therapeutics during the 4th quarter valued at approximately $68,000. Bank of America Corp DE lifted its holdings in VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after buying an additional 19,331 shares during the period. Finally, Tudor Investment Corp ET AL bought a new stake in shares of VistaGen Therapeutics in the 4th quarter worth approximately $50,000. 78.39% of the stock is owned by institutional investors.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.